Y Takeda

549 citations
30 papers · 466 indexed · h-index 10

Y Takeda

28 papers receiving 444 citations

Peers

Y Takeda
Comparison fields: 5 of 92
  • Oncology 168
  • Endocrine and Autonomic Systems 26
  • Molecular Biology 223
  • Toxicology 10
  • Aging 5
Replace Shihong Ma with:
Shihong Ma United States
Linping Hu China
Barnali Pramanik United States
Yuki Ishii Japan
Teruaki Katayama Japan
Yusuke Nakamura Japan
Vineet Sangar United States
Etsuo Nakamura Japan
Sumiko Hamanaka Japan
Ruonan Xu China
Y Takeda relative to Shihong Ma United States Shihong Ma's profile →
Citations per field
00.5×1.5×1.9×
Shihong Ma · 1×
Citations per year

Countries citing papers authored by Y Takeda

Since Specialization
Citations

This map shows the geographic impact of Y Takeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y Takeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y Takeda more than expected).

Fields of papers citing papers by Y Takeda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y Takeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y Takeda. The network helps show where Y Takeda may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Y Takeda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Y Takeda Line = papers co-authored together Y Takeda links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20057
2 20034
3 200344
4 200336
5 20020
6 20028
7 200211
8 20006
9 19986
10 19979
11 199712
12 19962
13 19952
14 1993145
15 19913
16
378 Total parenteral nutrition (TPN) using imbalanced (methionine deprived) aminoacids solution in chemotherapy for ovarian cancer.
19901
17 19906
18 19892
19 19815
20
[Collagen diseases (author's transl)].
19810

About Y Takeda

Y Takeda is a scholar working on Oncology, Cancer Research and Virology, having authored 30 papers that have together received 466 indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (3 papers), Cancer Treatment and Pharmacology (3 papers), Virus-based gene therapy research (2 papers), Cancer therapeutics and mechanisms (2 papers), Immunotherapy and Immune Responses (2 papers), HER2/EGFR in Cancer Research (2 papers), HIV/AIDS drug development and treatment (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Oncology (168 citations), Endocrine and Autonomic Systems (26 citations) and Molecular Biology (223 citations). Y Takeda has collaborated with scholars based in Japan, Nigeria and United States. Frequent co-authors include Masazumi Eriguchi, Hironobu Yanagië, Majekodunmi O. Fatope, Eckhard R. Podack, Taisuke Ohira, Tohru Ohmori, Naoto Kubota, Nagahiro Saijo, Minako Takahashi and Hideki Ogasawara. Their work appears in journals such as Journal of Clinical Investigation, JNCI Journal of the National Cancer Institute and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026